Bell , J.G., MacKinlay , E.E., Dick, J.R., et al
Real World Impact: Current Use and Outcomes These medications are no longer niche, they're influencing population level trends: Rapid Growth in Use In the U.S., reported use of GLP-1 weight loss drugs has more than doubled in the past year, from about 5.8% of adults in early 2024 to over 12% in 2025 Women tend to use these medications at higher rates than men, with 15.2% vs
Primarily, Ozempic regulates blood sugar levels by preventing the liver from overproducing sugar
Metformin targets intestinal immune system signaling pathways in a high-fat diet-induced mouse model of obesity and insulin resistance
This novel insight offers a fresh perspective on the mechanisms of tumor immune evasion and provides critical clues for the development of therapeutic strategies targeting the immune microenvironment [208]